NAVEGA THERAPEUTICS
Navega Therapeutics is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. At Navega, we have developed a novel gene therapy to treat severe chronic pain that is non-addictive, highly specific, and long lasting. We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by developing a novel gene therapy to target pain in a non-addictive way. I... n our proof of concept, we demonstrated that the mice that received our therapy have an increased pain tolerance and lower pain levels during weeks. We validated our approach in three preclinical animal models: inflammatory pain, chemotherapy-induced neuropathic pain and BzATP-induced pain. We also have safety studies demonstrating that our therapy has no neurological, motor, or olfactory side-effects. We have been awarded two SBIR grants, one from the National Cancer Institute and another one from the National Institute of Neurological Disorders and Stroke, and licensed three patents from UCSD.
NAVEGA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Neuroscience Therapeutics
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.navegatx.com
Total Employee:
1+
Status:
Active
Contact:
(858) 729-8345
Total Funding:
6.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Google Tag Manager Nginx Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Trefoil Therapeutics
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Current Employees Featured
Fernando Aleman Co-founder and CSO @ Navega Therapeutics
Co-founder and CSO
2018-01-01
Ana Moreno Founder & CEO @ Navega Therapeutics
Founder & CEO
2018-08-01
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Navega Therapeutics
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Navega Therapeutics
Creative Destruction Lab (CDL)
Creative Destruction Lab (CDL) investment in Non Equity Assistance - Navega Therapeutics
National Cancer Institute
National Cancer Institute investment in Grant - Navega Therapeutics
National Institute of Neurological Disorders and Stroke
National Institute of Neurological Disorders and Stroke investment in Grant - Navega Therapeutics
Newest Events participated
Participated in Biotech Showcase: Investor and Partnering Conference in San Francisco
on 2022-01-12 as speaker
Official Site Inspections
http://www.navegatx.com
- Host name: fatcobra.introbay.com
- IP address: 88.99.210.16
- Location: Morlenbach Germany
- Latitude: 49.5992
- Longitude: 8.7347
- Timezone: Europe/Berlin
- Postal: 69509
More informations about "Navega Therapeutics"
Navega Therapeutics | Gene Therapies for Chronic Pain and …
Harnessing the precision of zinc-finger and CRISPR based epigenome regulation to enable next-generation gene therapiesSee details»
Navega Therapeutics - Crunchbase Company Profile
Organization. Navega Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Scientist position | Navega Therapeutics
Contribute to general lab management and organization. Collaborate to design and implement SOPs. Preferred skills: Experience with iPSCs and primary cell culture. ... If interested in this position, please send your resume to …See details»
Senior Research Associate | Navega Therapeutics
Sep 2, 2021 Contribute to general lab management and organization. Collaborate with a team to design and implement SOPs. Preferred skills: Experience with iPSCs and primary cell culture. …See details»
Navega Therapeutics Overview | SignalHire Company Profile
Organization Website: navegatx.com : Navega Therapeutics industries Biotech: Headquarters Location: San Diego, CA, 92122 US San Diego, CA, 92122 US : Navega Therapeutics …See details»
NAVEGA THERAPEUTICS, INC. - VentureRadar
Navega Therapeutics is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common diseases. Instead of editing the... ... Find out ...See details»
Navega Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.navegatx.com. Startups | Private Company | 2018 | California, United States | < 10 | www.navegatx.com. Last update 06 Mar 2025. Overview. Pipeline. Deal. Translational …See details»
Company: Navega Therapeutics - crisprmedicinenews.com
Company Type: Therapeutic development Main focus: Developing novel therapeutics via zinc finger nuclease - and CRISPR-based epigenome regulation. Company stage: Pre-clinical. …See details»
Navega Therapeutics - Overview, News & Similar companies
Navega Therapeutics contact info: Phone number: (928) 750-1629 Website: www.navegatx.com What does Navega Therapeutics do? About Navega Therapeutics Inc. | Navega is a …See details»
Navega Therapeutics - Craft
Navega Therapeutics has 5 employees at their 1 location. See insights on Navega Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Ana Moreno PhD | Navega Therapeutics
Ana Moreno is the founder and CEO of Navega Therapeutics. She obtained her Ph.D. from the Bioengineering Department at UCSD , where she spent the last four years developing the platform that enables Navega’s innovative approach.See details»
Navega Therapeutics - CipherBio
Explore Navega Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Navega Therapeutics 2025 Company Profile: Valuation, Funding ...
Navega Therapeutics General Information Description. Developer of gene therapies designed to treat chronic pain and tackle the opioid epidemic. The company's therapies target pain that is …See details»
Navega Therapeutics - Products, Competitors, Financials, …
Headquarters Location. 3210 Merryfield Row . San Diego, California, 92121, United States. 858-729-8345See details»
Tales of a Startup: Navega Therapeutics - University of California, …
May 28, 2021 Bioengineering Alumna Ana Moreno Pioneers Epigenetic Gene-Therapy Technology As An Answer to Chronic Pain. May 28, 2021. UC San Diego licensed Navega …See details»
NAVEGA THERAPEUTICS APPOINTS NEW STRATEGIC ADVISORS …
Feb 13, 2025 Ostrove has served on multiple boards and is also a past Board member of the Biotechnology Innovation Organization (BIO). ... (928) 750-1629, amoreno@navegatx.com; …See details»
Advancing precision pain medicines to the clinic | SBIR.gov
Email: amoreno@navegatx.com. Research Institution. N/A . Abstract. Abstract Chronic pain is pain that persists past the normal time of healing. 1.5 billion people worldwide suffer from …See details»
Stephen Waxman MD, PhD | Navega Therapeutics
Stephen Waxman is the Flaherty Professor of Neurology, Neuroscience, and Pharmacology at Yale. His research has made pivotal contributions in injury to the brain, spinal cord, and …See details»
Ana Moreno | Institute for the Global Entrepreneur
Franklin Antonio Hall 3180 Voight Drive Suite 1401 La Jolla, CA 92093. Email: IGE@UCSD.EDUSee details»
Navega Therapeutics becomes a trusted partner of the HEAL …
Sep 26, 2019 Navega receives a SBIR grant to support the development of novel gene therapies to ameliorate chronic pain. San Diego, California. September 26, 2019.See details»